PP2A-B55-β Inhibitors

PP2A-B55-β inhibitors comprise a range of chemicals that target the PP2A protein complex, either directly or indirectly, affecting its regulatory subunit B55-β. PP2A is a serine/threonine phosphatase, crucial in various cellular processes, including cell cycle regulation, signal transduction, and apoptosis. Inhibitors like Okadaic Acid, Cantharidin, and LB-100 specifically target the PP2A complex, leading to alterations in its phosphatase activity. These inhibitors bind to the catalytic subunit of PP2A, leading to conformational changes and reduced dephosphorylation activity. This inhibition results in increased phosphorylation levels of various substrates, impacting cellular signaling pathways.

Calyculin A, Endothall, and Tautomycin, among others, also exhibit inhibitory effects on PP2A. These chemicals disrupt the PP2A-mediated regulation of critical cellular functions by altering the phosphorylation status of key proteins. For instance, Fostriecin selectively inhibits PP2A over other phosphatases, thereby specifically altering the PP2A-dependent pathways. Norcantharidin, a derivative of cantharidin, retains the PP2A inhibitory properties, affecting cellular processes such as apoptosis and cell proliferation. Additionally, indirect inhibitors like Phenothiazine and Ionomycin modulate PP2A activity by influencing related signaling cascades. Phenothiazine exerts its effect through modulation of neurotransmitter signaling, which can indirectly impact PP2A activity, while Ionomycin affects PP2A by altering calcium ion concentrations, crucial for various signaling pathways.